Skip to main content

Advertisement

Figure 9 | Arthritis Research & Therapy

Figure 9

From: Suppressive effect of secretory phospholipase A2inhibitory peptide on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice

Figure 9

Possible mechanism of PIP-18 suppression on IL-stimulated expression of sPLA2 and MMPs. IL-1β and/or TNF initiate the expression of secretory phospholipase A2 (sPLA2)-IIA and matrix metalloproteinases (MMP) through activation of mitogen-activated protein kinase (MAPK) cascade. (1) phospholipase inhibitor from python (PIP)-18 blocks p38 MAPK phosphorylation and reduces activation of transcription factors (activator protein-1 (AP-1), activating transcription factor 2 (ATF-2)), which regulate the transcription of sPLA2-IIA, MMPs (MMP-1, MMP-2, MMP-3, MMP-9) and proinflammatory cytokines (IL-6, TNF, IL-1). This results in downregulation of these genes and decreased protein secretions. (2) Inhibition of sPLA2 enzymatic activity by PIP-18 contributes to reduced generation of arachidonic acid for prostaglandin production. MAPKKK = MAPK kinase kinase; MAPKK = MAPK kinase; PGE2 = prostaglandin E2; sPLA2-IIA = secretory phospholipase A2-Group IIA; solid arrows, known pathways; , inhibition (NF-κB pathway is not shown here).

Back to article page